Bicara Therapeutics Inc. (BCAX) research
Bicara Therapeutics Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $17.63
- As of
Bicara Therapeutics Inc. (BCAX): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-25.
As of . Source: SEC EDGAR filings for BCAX. Method and limitations.
Share the BCAX intelligence card
See the full BCAX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for BCAX on one page. Preview it with sample data, then open it live with a free account.
Preview the BCAX dossierActive signals for BCAX
- highCONSENSUS_BUY
3 tracked funds increased BCAX this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +67% to BCAX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +273% to BCAX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +758% to BCAX (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +80% to BCAX (2026Q2)
FREE, NO ACCOUNT
Every signal on BCAX, as it fires
You are seeing 5 of 10 signals recorded on BCAX since 2026-06-15.
The five above landed across 2 days. The other 5 were recorded on 2 other days. 6 of the 10 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in BCAX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 055477103 · 2026Q2 | $14.8M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 055477103 · 2026Q2 | $7.8M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 055477103 · 2026Q2 | $6.3M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 055477103 · 2026Q2 | $1.4M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, BCAX
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
BCAX against its peers
BCAX's return on equity of -34.4% ranks in the 75th percentile of 9 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | BCAX | Peer median | Percentile | n |
|---|---|---|---|---|
| Return on equity | -34.4% | -55.3% | 75 | 9 |
Peers (13): LBRX, REPL, DMRA, IMTX, ORIC, DRTS, VOR, MNKD, RARE, MGTX, SVRA, INBX, TYRA. Left out: TRAX (no annual filing), AVLN (no annual filing), LTGO (no annual filing), KARD (no annual filing), AAPG (period gap), SLBT (no annual filing), AKTS (no annual filing), KALV (no annual filing), COAG (no annual filing), KLRA (no annual filing), SPTX (no annual filing), ODTX (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (BCAX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more BCAX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to BCAXand get the insider, 13F, options, and confluence read in one view.